GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (OTCPK:LBLTF) » Definitions » Quick Ratio

Lattice Biologics (Lattice Biologics) Quick Ratio : 0.00 (As of Jun. 2021)


View and export this data going back to 2001. Start your Free Trial

What is Lattice Biologics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Lattice Biologics's quick ratio for the quarter that ended in Jun. 2021 was 0.00.

Lattice Biologics has a quick ratio of 0.00. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Lattice Biologics's Quick Ratio or its related term are showing as below:

LBLTF's Quick Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.06
* Ranked among companies with meaningful Quick Ratio only.

Lattice Biologics Quick Ratio Historical Data

The historical data trend for Lattice Biologics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Quick Ratio Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.04 0.03 0.04 0.05

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.03 0.02 -

Competitive Comparison of Lattice Biologics's Quick Ratio

For the Medical Devices subindustry, Lattice Biologics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lattice Biologics's Quick Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Lattice Biologics's Quick Ratio falls into.



Lattice Biologics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Lattice Biologics's Quick Ratio for the fiscal year that ended in Sep. 2020 is calculated as

Quick Ratio (A: Sep. 2020 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.902-0.519)/7.832
=0.05

Lattice Biologics's Quick Ratio for the quarter that ended in Jun. 2021 is calculated as

Quick Ratio (Q: Jun. 2021 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0-0)/0.506
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lattice Biologics  (OTCPK:LBLTF) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Lattice Biologics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lattice Biologics (Lattice Biologics) Business Description

Traded in Other Exchanges
N/A
Address
512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (Lattice Biologics) Headlines

No Headlines